Programm & Abstracts                 "Innovationen in der Augenheilkunde"

Aktuelle Tagungsinformationen
   News and Updates

Anmeldung zur Tagung
   Registration
Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Collateral Events
Rahmenprogramm
   Social program
Jubiläumsparty
   Jubilee Party
DOG Information
   DOG Information
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Ausstellerliste
   Exhibitors
Sponsoren
   Sponsors
Teilnahmegebühren
   Registration fees
Impressum



DOG Homepage

ILM PEELING and/or Triamcinolone in Persistent Diabetic Macular Edema (TIME-Study)

Joussen A. M., Kirchhof B.,
Universität zu Köln, Zentrum für Augenheilkunde, Abteilung für Netzhaut- und Glaskörperchirurgie (Köln)

Patients: Patients with persistent macular edema as a consequence of diabetic maculopathy
Treatments: Group 0: Observation: in this group the lens status will be determined according to LOCS 3 at each visit. In case of deterioration of V/A as a consequence of cataract formation, cataract surgery and IOL implantation will be performed TRIAMCINOLONE (4MG) INTRAVITREAL AND/OR ILM PEELING: All patients will undergo cataract surgery and IOL implantation at the time of the operation: Group 1: ppV and posterior vitreous detachment; Group 2: ppV and posterior vitreous detachment + ILM peeling; Group 3: ppV and posterior vitreous detachment and ILM peeling + triamcinolone 4 mg at time of surgery and after every visit (8 weekly); Group 4: triamcinolone 4 mg at every visit (8 weekly).
Inclusion Criteria: Persistent (diffuse or focal) macular edema (>6 month) as demonstrated by fluorescein angiography according to ETDRS criteria for CSME associated with diabetes
Exclusion Criteria: ischemic maculopathy (foveal avascular zone > 800 µm according to grade 3 ETDRS); proliferative retinopathy and associated complications such as bleeding and tractional detachment (ADED); additional ocular diseases reducing the visual acuity: retinal artery occlusion, glaucoma in a late stage, mature cataract, choriodal neovascularization, uveitis; age <18; cataract surgery less than twelve month before treatment· known cortico-steroid responder; complications during surgery requiring endotamponade; change of current long-term treatment with vasoactive substances such as non-steroidal antiinflammatory drugs or steroids
Examinations: Measurement of visual acuity, reading speed, contrast sensivity, colour vision; fluorescein angiography of the retinal vasculature; stereo fundus photography; retinal thickness measurement with optical coherence tomography (OCT); quality of life questionnaire
Primary Endpoint: 2 month distant visual acuity (ETDRS), · 12 month distand visual acuity (ETDRS)
Secondary Endpoint: 2, 4, 6, 12 month visual acuity; reading performance at 2, 4, 6 and 12 month (Radner-Test); changes in retinal thickness as measured by OCT at all time points; determination of vascular leakage by fluorescein angiography at all time points; quality of life questionnaire; contrast sensitivity, colour vision; long term glucose control (HbA1c), Type I or Type II diabetes, insulin treatment
Principal clinical Investigators: Priv.-Doz. Dr. Antonia M. Joussen, Köln; Prof. Dr. Bernd Kirchhof, Köln
Status: Ethics comittee: applied; Funding: Application in preparation; Study centers/physicians: still open

Zurück/Back